Swedbank buys $337.5 Million stake in Henry Schein (HSIC)

Henry Schein (HSIC) : Swedbank scooped up 58,623 additional shares in Henry Schein during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 1,962,684 shares of Henry Schein which is valued at $337.5 Million.Henry Schein makes up approximately 2.82% of Swedbank’s portfolio.

Other Hedge Funds, Including , Amalgamated Bank boosted its stake in HSIC in the latest quarter, The investment management firm added 784 additional shares and now holds a total of 3,311 shares of Henry Schein which is valued at $569,393. Henry Schein makes up approx 0.06% of Amalgamated Bank’s portfolio.Massmutual Trust Co Fsbadv boosted its stake in HSIC in the latest quarter, The investment management firm added 197 additional shares and now holds a total of 5,129 shares of Henry Schein which is valued at $882,034. Henry Schein makes up approx 0.12% of Massmutual Trust Co Fsbadv’s portfolio. Kalos Management sold out all of its stake in HSIC during the most recent quarter. The investment firm sold 67,547 shares of HSIC which is valued $11.5 Million. Dupont Capital Management Corp sold out all of its stake in HSIC during the most recent quarter. The investment firm sold 8,727 shares of HSIC which is valued $1.5 Million.

Henry Schein opened for trading at $171.63 and hit $174.45 on the upside on Monday, eventually ending the session at $174.13, with a gain of 1.26% or 2.16 points. The heightened volatility saw the trading volume jump to 3,58,730 shares. Company has a market cap of $14,290 M.

On the company’s financial health, Henry Schein reported $1.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $1.39. The company had revenue of $2712.96 million for the quarter, compared to analysts expectations of $2667.28 million. The company’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.28 EPS.

Many Wall Street Analysts have commented on Henry Schein. Company shares were Reiterated by Barrington Research on May 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 188 from a previous price target of $182 .Henry Schein was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016. Barrington Research Upgraded Henry Schein on Mar 1, 2016 to ” Outperform”, Price Target of the shares are set at $182.

Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.

Leave a Reply

Henry Schein - Is it time to Sell?

Top Brokerage Firms are advising their investors on Henry Schein. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.